ParkinsonFranceV1, Hal, Curation, bibRecord, 000713

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats

Identifieur interne : 000713 ( Hal/Curation ); précédent : 000712; suivant : 000714

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats

Auteurs : A. El Arfani ; E. Bentea ; N. Aourz ; B. Ampe ; P. De Deurwaerdère [France] ; A. Van Eeckhaut ; A. Massie ; S. Sarre ; I. Smolders ; Y. Michotte

Source :

Neuropharmacology [ 0028-3908 ] ; 2014.

RBID : Hal:hal-01379573

Abstract

Long term treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) is associated with several motor complications. Clinical improvement of this treatment is therefore needed. Lesions or high frequency stimulation of the hyperactive subthalamic nucleus (STN) in Parkinson's disease (PD), alleviate the motor symptoms and reduce dyskinesia, either directly and/or by allowing the reduction of the L-DOPA dose. N-methyl-D-aspartate (NMDA) receptor antagonists might have similar actions. However it remains elusive how the neurochemistry changes in the STN after a separate or combined administration of L-DOPA and a NMDA receptor antagonist. By means of in vivo microdialysis, the effect of L-DOPA and/or MK 801, on the extracellular dopamine (DA) and glutamate (GLU) levels was investigated for the first time in the STN of sham and 6-hydroxydopamine-lesioned rats. The L-DOPA-induced DA increase in the STN was significantly higher in DA-depleted rats compared to shams. MK 801 did not influence the L-DOPA-induced DA release in shams. However, MK 801 enhanced the L-DOPA-induced DA release in hemi-parkinson rats. Interestingly, the extracellular STN GLU levels remained unchanged after nigral degeneration. Furthermore, administration of MK 801 alone or combined with L-DOPA did not alter the STN GLU levels in both sham and DA-depleted rats. The present study does not support the hypothesis that DA-ergic degeneration influences the STN GLU levels neither that MK 801 alters the GLU levels in lesioned and non-lesioned rats. However, NMDA receptor antagonists could be used as a beneficial adjuvant treatment for PD by enhancing the therapeutic efficacy of l-DOPA at least in part in the STN.

Url:

https://hal.archives-ouvertes.fr/hal-01379573

DOI: 10.1016/j.neuropharm.2014.05.024

Links toward previous steps (curation, corpus...)

to stream Hal, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000777

Links to Exploration step

Hal:hal-01379573

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats</title>
<author><name sortKey="El Arfani, A" sort="El Arfani, A" uniqKey="El Arfani A" first="A" last="El Arfani">A. El Arfani</name>
</author>
<author><name sortKey="Bentea, E" sort="Bentea, E" uniqKey="Bentea E" first="E" last="Bentea">E. Bentea</name>
</author>
<author><name sortKey="Aourz, N" sort="Aourz, N" uniqKey="Aourz N" first="N" last="Aourz">N. Aourz</name>
</author>
<author><name sortKey="Ampe, B" sort="Ampe, B" uniqKey="Ampe B" first="B" last="Ampe">B. Ampe</name>
</author>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID">  <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
  <orgName type="acronym">IMN</orgName>
  <desc>    <address>      <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://imn-bordeaux.org/</ref>
  </desc>
  <listRelation>    <relation active="#struct-259761" type="direct"></relation>
    <relation name="UMR5293" active="#struct-441569" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID">  <orgName>Université de Bordeaux</orgName>
  <orgName type="acronym">UB</orgName>
  <desc>    <address>      <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://www.u-bordeaux.fr/</ref>
  </desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID">  <idno type="IdRef">02636817X</idno>
  <idno type="ISNI">0000000122597504</idno>
  <orgName>Centre National de la Recherche Scientifique</orgName>
  <orgName type="acronym">CNRS</orgName>
  <date type="start">1939-10-19</date>
  <desc>    <address>      <country key="FR"></country>
    </address>
    <ref type="url">http://www.cnrs.fr/</ref>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName><settlement type="city">Bordeaux</settlement>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author><name sortKey="Van Eeckhaut, A" sort="Van Eeckhaut, A" uniqKey="Van Eeckhaut A" first="A" last="Van Eeckhaut">A. Van Eeckhaut</name>
</author>
<author><name sortKey="Massie, A" sort="Massie, A" uniqKey="Massie A" first="A" last="Massie">A. Massie</name>
</author>
<author><name sortKey="Sarre, S" sort="Sarre, S" uniqKey="Sarre S" first="S" last="Sarre">S. Sarre</name>
</author>
<author><name sortKey="Smolders, I" sort="Smolders, I" uniqKey="Smolders I" first="I" last="Smolders">I. Smolders</name>
</author>
<author><name sortKey="Michotte, Y" sort="Michotte, Y" uniqKey="Michotte Y" first="Y" last="Michotte">Y. Michotte</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-01379573</idno>
<idno type="halId">hal-01379573</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-01379573</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-01379573</idno>
<idno type="doi">10.1016/j.neuropharm.2014.05.024</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Hal/Corpus">000777</idno>
<idno type="wicri:Area/Hal/Curation">000777</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats</title>
<author><name sortKey="El Arfani, A" sort="El Arfani, A" uniqKey="El Arfani A" first="A" last="El Arfani">A. El Arfani</name>
</author>
<author><name sortKey="Bentea, E" sort="Bentea, E" uniqKey="Bentea E" first="E" last="Bentea">E. Bentea</name>
</author>
<author><name sortKey="Aourz, N" sort="Aourz, N" uniqKey="Aourz N" first="N" last="Aourz">N. Aourz</name>
</author>
<author><name sortKey="Ampe, B" sort="Ampe, B" uniqKey="Ampe B" first="B" last="Ampe">B. Ampe</name>
</author>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-244085" status="VALID">  <orgName>Institut des Maladies Neurodégénératives [Bordeaux]</orgName>
  <orgName type="acronym">IMN</orgName>
  <desc>    <address>      <addrLine>Bât. 3b 1er étage 146 Rue Léo Saignat 33076 Bordeaux </addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://imn-bordeaux.org/</ref>
  </desc>
  <listRelation>    <relation active="#struct-259761" type="direct"></relation>
    <relation name="UMR5293" active="#struct-441569" type="direct"></relation>
  </listRelation>
<tutelles><tutelle active="#struct-259761" type="direct"><org type="institution" xml:id="struct-259761" status="VALID">  <orgName>Université de Bordeaux</orgName>
  <orgName type="acronym">UB</orgName>
  <desc>    <address>      <addrLine>35, place Pey Berland - 33076 Bordeaux</addrLine>
      <country key="FR"></country>
    </address>
    <ref type="url">http://www.u-bordeaux.fr/</ref>
  </desc>
</org>
</tutelle>
<tutelle name="UMR5293" active="#struct-441569" type="direct"><org type="institution" xml:id="struct-441569" status="VALID">  <idno type="IdRef">02636817X</idno>
  <idno type="ISNI">0000000122597504</idno>
  <orgName>Centre National de la Recherche Scientifique</orgName>
  <orgName type="acronym">CNRS</orgName>
  <date type="start">1939-10-19</date>
  <desc>    <address>      <country key="FR"></country>
    </address>
    <ref type="url">http://www.cnrs.fr/</ref>
  </desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>France</country>
<placeName><settlement type="city">Bordeaux</settlement>
<region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
</placeName>
<orgName type="university">Université de Bordeaux</orgName>
</affiliation>
</author>
<author><name sortKey="Van Eeckhaut, A" sort="Van Eeckhaut, A" uniqKey="Van Eeckhaut A" first="A" last="Van Eeckhaut">A. Van Eeckhaut</name>
</author>
<author><name sortKey="Massie, A" sort="Massie, A" uniqKey="Massie A" first="A" last="Massie">A. Massie</name>
</author>
<author><name sortKey="Sarre, S" sort="Sarre, S" uniqKey="Sarre S" first="S" last="Sarre">S. Sarre</name>
</author>
<author><name sortKey="Smolders, I" sort="Smolders, I" uniqKey="Smolders I" first="I" last="Smolders">I. Smolders</name>
</author>
<author><name sortKey="Michotte, Y" sort="Michotte, Y" uniqKey="Michotte Y" first="Y" last="Michotte">Y. Michotte</name>
</author>
</analytic>
<idno type="DOI">10.1016/j.neuropharm.2014.05.024</idno>
<series><title level="j">Neuropharmacology</title>
<idno type="ISSN">0028-3908</idno>
<imprint><date type="datePub">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Long term treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) is associated with several motor complications. Clinical improvement of this treatment is therefore needed. Lesions or high frequency stimulation of the hyperactive subthalamic nucleus (STN) in Parkinson's disease (PD), alleviate the motor symptoms and reduce dyskinesia, either directly and/or by allowing the reduction of the L-DOPA dose. N-methyl-D-aspartate (NMDA) receptor antagonists might have similar actions. However it remains elusive how the neurochemistry changes in the STN after a separate or combined administration of L-DOPA and a NMDA receptor antagonist. By means of in vivo microdialysis, the effect of L-DOPA and/or MK 801, on the extracellular dopamine (DA) and glutamate (GLU) levels was investigated for the first time in the STN of sham and 6-hydroxydopamine-lesioned rats. The L-DOPA-induced DA increase in the STN was significantly higher in DA-depleted rats compared to shams. MK 801 did not influence the L-DOPA-induced DA release in shams. However, MK 801 enhanced the L-DOPA-induced DA release in hemi-parkinson rats. Interestingly, the extracellular STN GLU levels remained unchanged after nigral degeneration. Furthermore, administration of MK 801 alone or combined with L-DOPA did not alter the STN GLU levels in both sham and DA-depleted rats. The present study does not support the hypothesis that DA-ergic degeneration influences the STN GLU levels neither that MK 801 alters the GLU levels in lesioned and non-lesioned rats. However, NMDA receptor antagonists could be used as a beneficial adjuvant treatment for PD by enhancing the therapeutic efficacy of l-DOPA at least in part in the STN.</div>
</front>
</TEI>
<hal api="V3">          <titleStmt>            <title xml:lang="en">NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats</title>
            <author role="aut">              <persName>                <forename type="first">A</forename>
                <surname>El Arfani</surname>
              </persName>
              <idno type="halauthorid">1396343</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">E</forename>
                <surname>Bentea</surname>
              </persName>
              <idno type="halauthorid">1396344</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">N</forename>
                <surname>Aourz</surname>
              </persName>
              <idno type="halauthorid">1396345</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">B</forename>
                <surname>Ampe</surname>
              </persName>
              <idno type="halauthorid">1396346</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">P</forename>
                <surname>De Deurwaerdère</surname>
              </persName>
              <idno type="halauthorid">1190869</idno>
              <affiliation ref="#struct-244085"></affiliation>
            </author>
            <author role="aut">              <persName>                <forename type="first">A</forename>
                <surname>Van Eeckhaut</surname>
              </persName>
              <idno type="halauthorid">1396347</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">A</forename>
                <surname>Massie</surname>
              </persName>
              <idno type="halauthorid">1396348</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">S</forename>
                <surname>Sarre</surname>
              </persName>
              <idno type="halauthorid">1396349</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">I</forename>
                <surname>Smolders</surname>
              </persName>
              <idno type="halauthorid">1396350</idno>
            </author>
            <author role="aut">              <persName>                <forename type="first">Y</forename>
                <surname>Michotte</surname>
              </persName>
              <idno type="halauthorid">1396351</idno>
            </author>
            <editor role="depositor">              <persName>                <forename>Philippe</forename>
                <surname>De Deurwaerdere</surname>
              </persName>
              <email type="md5">ea9841169841792cc22b5da7df57965f</email>
              <email type="domain">u-bordeaux.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>            <edition n="v1" type="current">              <date type="whenSubmitted">2016-10-11 17:04:29</date>
              <date type="whenModified">2016-10-12 01:00:48</date>
              <date type="whenReleased">2016-10-11 17:04:29</date>
              <date type="whenProduced">2014</date>
            </edition>
            <respStmt>              <resp>contributor</resp>
              <name key="457483">                <persName>                  <forename>Philippe</forename>
                  <surname>De Deurwaerdere</surname>
                </persName>
                <email type="md5">ea9841169841792cc22b5da7df57965f</email>
                <email type="domain">u-bordeaux.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>            <distributor>CCSD</distributor>
            <idno type="halId">hal-01379573</idno>
            <idno type="halUri">https://hal.archives-ouvertes.fr/hal-01379573</idno>
            <idno type="halBibtex">elarfani:hal-01379573</idno>
            <idno type="halRefHtml">Neuropharmacology, Elsevier, 2014, 85, pp.198-205. <10.1016/j.neuropharm.2014.05.024></idno>
            <idno type="halRef">Neuropharmacology, Elsevier, 2014, 85, pp.198-205. <10.1016/j.neuropharm.2014.05.024></idno>
          </publicationStmt>
          <seriesStmt>            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
          </seriesStmt>
          <notesStmt>            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>            <biblStruct>              <analytic>                <title xml:lang="en">NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats</title>
                <author role="aut">                  <persName>                    <forename type="first">A</forename>
                    <surname>El Arfani</surname>
                  </persName>
                  <idno type="halauthorid">1396343</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">E</forename>
                    <surname>Bentea</surname>
                  </persName>
                  <idno type="halauthorid">1396344</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">N</forename>
                    <surname>Aourz</surname>
                  </persName>
                  <idno type="halauthorid">1396345</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">B</forename>
                    <surname>Ampe</surname>
                  </persName>
                  <idno type="halauthorid">1396346</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">P</forename>
                    <surname>De Deurwaerdère</surname>
                  </persName>
                  <idno type="halauthorid">1190869</idno>
                  <affiliation ref="#struct-244085"></affiliation>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">A</forename>
                    <surname>Van Eeckhaut</surname>
                  </persName>
                  <idno type="halauthorid">1396347</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">A</forename>
                    <surname>Massie</surname>
                  </persName>
                  <idno type="halauthorid">1396348</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">S</forename>
                    <surname>Sarre</surname>
                  </persName>
                  <idno type="halauthorid">1396349</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">I</forename>
                    <surname>Smolders</surname>
                  </persName>
                  <idno type="halauthorid">1396350</idno>
                </author>
                <author role="aut">                  <persName>                    <forename type="first">Y</forename>
                    <surname>Michotte</surname>
                  </persName>
                  <idno type="halauthorid">1396351</idno>
                </author>
              </analytic>
              <monogr>                <idno type="halJournalId" status="VALID">14921</idno>
                <idno type="issn">0028-3908</idno>
                <title level="j">Neuropharmacology</title>
                <imprint>                  <publisher>Elsevier</publisher>
                  <biblScope unit="volume">85</biblScope>
                  <biblScope unit="pp">198-205</biblScope>
                  <date type="datePub">2014</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/j.neuropharm.2014.05.024</idno>
              <idno type="pubmed">24863042</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>            <langUsage>              <language ident="en">English</language>
            </langUsage>
            <textClass>              <classCode scheme="halDomain" n="sdv.neu.nb">Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology</classCode>
              <classCode scheme="halDomain" n="sdv.sp.pharma">Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">Long term treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) is associated with several motor complications. Clinical improvement of this treatment is therefore needed. Lesions or high frequency stimulation of the hyperactive subthalamic nucleus (STN) in Parkinson's disease (PD), alleviate the motor symptoms and reduce dyskinesia, either directly and/or by allowing the reduction of the L-DOPA dose. N-methyl-D-aspartate (NMDA) receptor antagonists might have similar actions. However it remains elusive how the neurochemistry changes in the STN after a separate or combined administration of L-DOPA and a NMDA receptor antagonist. By means of in vivo microdialysis, the effect of L-DOPA and/or MK 801, on the extracellular dopamine (DA) and glutamate (GLU) levels was investigated for the first time in the STN of sham and 6-hydroxydopamine-lesioned rats. The L-DOPA-induced DA increase in the STN was significantly higher in DA-depleted rats compared to shams. MK 801 did not influence the L-DOPA-induced DA release in shams. However, MK 801 enhanced the L-DOPA-induced DA release in hemi-parkinson rats. Interestingly, the extracellular STN GLU levels remained unchanged after nigral degeneration. Furthermore, administration of MK 801 alone or combined with L-DOPA did not alter the STN GLU levels in both sham and DA-depleted rats. The present study does not support the hypothesis that DA-ergic degeneration influences the STN GLU levels neither that MK 801 alters the GLU levels in lesioned and non-lesioned rats. However, NMDA receptor antagonists could be used as a beneficial adjuvant treatment for PD by enhancing the therapeutic efficacy of l-DOPA at least in part in the STN.</abstract>
          </profileDesc>
        </hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Hal/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000713 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Hal/Curation/biblio.hfd -nk 000713 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Hal
   |étape=   Curation
   |type=    RBID
   |clé=     Hal:hal-01379573
   |texte=   NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats

NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri